{"favorite_id": 3081, "calc_type": "", "dosing": false, "full_title_en": "NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score", "short_title_en": "NAFLD Fibrosis Score", "medium_description_en": "Estimates amount of scarring in the liver based on several laboratory tests.", "short_description_en": "Estimates amount of liver scarring.", "before_use": "", "instructions_en": "", "purpose_en": ["Calculation"], "disease_en": ["Cirrhosis", "Hepatitis", "Diabetes Mellitus"], "specialty_en": ["Endocrinology", "Gastroenterology", "Hepatology", "Internal Medicine"], "chief_complaint_en": ["Abdominal Pain", "Jaundice"], "system_en": ["Endocrine and Metabolic", "Gastrointestinal"], "search_abbreviation_en": ["hepatic", "nafld", "fibrosis", "cirrhosis", "prognosis", "calculation", "hepatitis"], "slug": "nafld-non-alcoholic-fatty-liver-disease-fibrosis-score", "seo": {"meta_description_en": "The NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score estimates amount of scarring in the liver based on several laboratory tests.", "keywords_en": "NAFLD fibrosis score, nafld score, nafld fibrosis, nafld F1, nafld F2, nafld F3, nafld F4, NAFLD calc, nafld fibrosis calc, fibrosis severity calc, fibrosis severity mdcalc, fibrosis severity score, fibrosis severity prognosis, fibrosis prognosis, nafld prognosis, fibrosis, cirrhosis, NAFLD cirrhosis, cirrhosis NAFLD score, cirrhosis calc"}, "content": {"how_to_use": {"use_case_en": "<p>Patients who have been identified to have NAFLD.</p>", "pearls_pitfalls_en": "<ul> <li>Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in the world.</li> <li>Many NAFLD patients will have little progression in their disease, however a subset will progress to liver fibrosis and cirrhosis.</li> <li>Patients studied to develop this score were screened for other causes of liver disease and were specifically evaluated closely for concomitant alcohol. Patients with already-decompensated liver disease by clinical or imaging evidence were also excluded.</li> <li>Patients with NAFLD should have their fibrosis scores trended over time to evaluate for progression or stabilization.</li> <li>The NAFLD can reduce liver biopsies in those patients predicted to have a low risk of fibrosis by their score: \u201ca liver biopsy to determine severity of fibrosis would be required in only 25% of patients with NAFLD, that is, those identified as \u2018indeterminate\u2019.\u201d</li> </ul>", "why_use_en": "<ul> <li>Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver cirrhosis are high risk for progression to end-stage liver disease.</li> <li>Patients with known liver fibrosis should have their fibrosis trended over time to evaluate for progression or stabilization.</li> </ul>"}, "next_steps": {"advice_en": "<p>Depending on score and local prevalence of advanced fibrosis, the score can be used to reliably predict (with high 80-low 90% accuracy) which patients are unlikely to have cellular evidence of fibrosis on biopsy.</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p>NAFLD Score = -1.675 + (0.037*age [years]) + (0.094*BMI [kg/m<sup>2</sup>]) + (1.13*IFG/diabetes [yes = 1, no = 0]) + (0.99*AST/ALT ratio) \u2013 (0.013*platelet count [\u00d710<sup>9</sup>/L]) \u2013 (0.66*albumin [g/dl])</p>", "more_info_en": "<div class=\"table-responsive\"> <table class=\"table table-bordered table-hover\"> <tbody> <tr> <th>NAFLD Score</th> <th>Correlated Fibrosis Severity</th> </tr> <tr> <td>&lt; -1.455</td> <td>F0-F2</td> </tr> <tr> <td>-1.455 \u2013 0.675</td> <td>Indeterminant score</td> </tr> <tr> <td>&gt; 0.675</td> <td>F3-F4</td> </tr> </tbody> </table> </div> <p>Fibrosis Severity Scale</p> <ul> <li>F0 = no fibrosis</li> <li>F1 = mild fibrosis</li> <li>F2 = moderate fibrosis</li> <li>F3 = severe fibrosis</li> <li>F4 = cirrhosis</li> </ul>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/17393509", "text": "Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54. PMID: 17393509."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/28834467", "text": "Tapper EB, Lok AS. Use of Liver Imaging and Biopsy in Clinical Practice. N Engl J Med. 2017;377(8):756-768."}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587478/", "text": "Treeprasertsuk S, Bj\u00f6rnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World Journal of Gastroenterology. 2013;19(8):1219-1229. doi:10.3748/wjg.v19.i8.1219."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "<p>Graham Walker, MD, is an emergency physician practicing in San Francisco, California. Dr. Walker attended medical school at the Stanford University School of Medicine and then trained in emergency medicine at St. Luke\u2019s-Roosevelt Hospital Center in New York City, where he was Chief Resident. He returned to the west coast as a Medical Simulation fellow and attending in Stanford\u2019s emergency department. More relevant, of course, is that Dr. Walker is the creator and developer of MDCalc and remains active in content and calculator development, along with our many other endeavors as President of MD Aware, LLC (MDCalc\u2019s parent company).</p>", "firstName": "Graham", "img": "https://cdn-web-img.mdcalc.com/people/graham-walker.jpg", "lastName": "Walker", "name": "Graham Walker, MD", "target": "graham-walker", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Paul Angulo", "creator_info": {"about_en": "<p>Paul Angulo, MD,\u00a0(d. 2015)\u00a0was a professor of medicine at the University of Kentucky after spending 12 years at the Mayo Clinic in Rochester, Minnesota, where he worked as associate professor of medicine. He specialized in general hepatology, non-alcoholic fatty liver disease, cholestatic liver disease, and autoimmune hepatitis. Dr. Angulo was on the editorial board of numerous medical journals and has authored more than 240 articles, abstracts, book reviews, and editorials.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-paul-angulo.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Angulo+P%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "textbox", "label_en": "Age", "name": "age", "unit": "age", "conditionality": "", "optional": false, "unit_info": {"name": "Age", "conversion": 1, "error_min": 0.001, "error_max": 120, "warn_min": 0.1, "warn_max": 100, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "years", "units_us": "years"}}, {"type": "textbox", "label_en": "BMI", "name": "bmi", "unit": "BMI", "conditionality": "", "optional": false, "unit_info": {"name": "Body Mass Index", "conversion": 1, "error_min": 0, "error_max": 50, "warn_min": 10, "warn_max": 30, "normal_max_si": 25, "normal_min_si": 20, "normal_min_us": 20, "units_si": "kg/m\u00b2", "units_us": "kg/m\u00b2", "normal_max_us": 25}}, {"type": "toggle", "label_en": "Impaired fasting glucose/diabetes", "name": "ifg", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "textbox", "label_en": "<abbr title='Aspartate aminotransferase'>AST</abbr>", "name": "ast", "unit": "AST", "conditionality": "", "optional": false, "unit_info": {"name": "Aspartate Aminotransferase", "conversion": 1, "error_min": 1, "error_max": 10000, "warn_min": 4, "warn_max": 4000, "normal_max_si": 41, "normal_min_si": 15, "normal_min_us": 15, "units_si": "U/L", "units_us": "U/L", "normal_max_us": 41}}, {"type": "textbox", "label_en": "<abbr title='Alanine aminotransferase'>ALT</abbr>", "name": "alt", "unit": "ALT", "conditionality": "", "optional": false, "unit_info": {"name": "Alanine Aminotransferase", "conversion": 1, "error_min": 1, "error_max": 1000, "warn_min": 4, "warn_max": 400, "normal_max_si": 35, "normal_min_si": 1, "normal_min_us": 1, "units_si": "U/L", "units_us": "U/L", "normal_max_us": 35}}, {"type": "textbox", "label_en": "Platelet count", "name": "platelets", "unit": "plt", "conditionality": "", "optional": false, "unit_info": {"name": "Platelet Count", "conversion": 1, "error_min": 1, "error_max": 3200, "warn_min": 10, "warn_max": 750, "normal_max_si": 350, "normal_min_si": 150, "normal_min_us": 150, "units_si": "\u00d7 10\u2079/L", "units_us": "\u00d7 10\u00b3/\u00b5L", "normal_max_us": 350}}, {"type": "textbox", "label_en": "Albumin", "name": "alb", "unit": "alb", "conditionality": "", "optional": false, "unit_info": {"name": "Albumin", "conversion": 10, "error_min": 0, "error_max": 7, "warn_min": 1, "warn_max": 6, "normal_max_si": 55, "normal_min_si": 35, "normal_min_us": 3.5, "units_si": "g/L", "units_us": "g/dL", "normal_max_us": 5.5}}], "md5": "30337ad27e8dcfa18a06d414658ab454", "cmeVersion": "3081.1", "related_calcs": [{"calcId": 2200, "short_title_en": "FIB-4 Index", "slug": "fibrosis-4-fib-4-index-liver-fibrosis"}, {"calcId": 87, "short_title_en": "PELD Score", "slug": "peld-score-pediatric-end-stage-liver-disease-younger-12"}, {"calcId": 3094, "short_title_en": "APRI", "slug": "ast-platelet-ratio-index-apri"}]}